These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

187 related items for PubMed ID: 36194315

  • 1. The impact of cycleanine in cancer research: a computational study.
    Nwaefulu ON, Al-Shar'i NA, Owolabi JO, Sagineedu SR, Woei LC, Wai LK, Islam MK, Jayanthi S, Stanslas J.
    J Mol Model; 2022 Oct 04; 28(11):340. PubMed ID: 36194315
    [Abstract] [Full Text] [Related]

  • 2. Rapamycin-resistant poly (ADP-ribose) polymerase-1 overexpression is a potential therapeutic target in lymphangioleiomyomatosis.
    Sun Y, Gallacchi D, Zhang EY, Reynolds SB, Robinson L, Malinowska IA, Chiou TT, Pereira AM, Li C, Kwiatkowski DJ, Lee PS, Yu JJ.
    Am J Respir Cell Mol Biol; 2014 Dec 04; 51(6):738-49. PubMed ID: 24874429
    [Abstract] [Full Text] [Related]

  • 3. Leveraging shape screening and molecular dynamics simulations to optimize PARP1-Specific chemo/radio-potentiators for antitumor drug design.
    Khizer H, Maryam A, Ansari A, Ahmad MS, Khalid RR.
    Arch Biochem Biophys; 2024 Jun 04; 756():110010. PubMed ID: 38642632
    [Abstract] [Full Text] [Related]

  • 4. Poly (ADP-ribose) polymerase-1: an emerging target in right ventricle dysfunction associated with pulmonary hypertension.
    Kaur G, Singh N, Lingeshwar P, Siddiqui HH, Hanif K.
    Pulm Pharmacol Ther; 2015 Feb 04; 30():66-79. PubMed ID: 25481773
    [Abstract] [Full Text] [Related]

  • 5. [PARP1 inhibitors: contemporary attempts at their use in anticancer therapy and future perspective].
    Wiśnik E, Ryksa M, Koter-Michalak M.
    Postepy Hig Med Dosw (Online); 2016 Apr 13; 70():280-94. PubMed ID: 27117104
    [Abstract] [Full Text] [Related]

  • 6. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
    Yuan B, Ye N, Song SS, Wang YT, Song Z, Chen HD, Chen CH, Huan XJ, Wang YQ, Su Y, Shen YY, Sun YM, Yang XY, Chen Y, Guo SY, Gan Y, Gao ZW, Chen XY, Ding J, He JX, Zhang A, Miao ZH.
    Cancer Lett; 2017 Feb 01; 386():47-56. PubMed ID: 27847302
    [Abstract] [Full Text] [Related]

  • 7. Design, synthesis, and biological evaluation of novel chrysin derivatives as poly(ADP-ribose) polymerase 1 (PARP1) inhibitors for the treatment of breast cancer.
    Yang Y, Tong J, Xie X, Cao H, Fu Y, Luo Y, Liu S, Chen W, Yang N.
    Chin J Nat Med; 2024 May 01; 22(5):455-465. PubMed ID: 38796218
    [Abstract] [Full Text] [Related]

  • 8. Medicinal chemistry approaches of poly ADP-Ribose polymerase 1 (PARP1) inhibitors as anticancer agents - A recent update.
    Jain PG, Patel BD.
    Eur J Med Chem; 2019 Mar 01; 165():198-215. PubMed ID: 30684797
    [Abstract] [Full Text] [Related]

  • 9. Proteomic Analysis of the Downstream Signaling Network of PARP1.
    Zhen Y, Yu Y.
    Biochemistry; 2018 Jan 30; 57(4):429-440. PubMed ID: 29327913
    [Abstract] [Full Text] [Related]

  • 10. Enhanced killing of cancer cells by poly(ADP-ribose) polymerase inhibitors and topoisomerase I inhibitors reflects poisoning of both enzymes.
    Patel AG, Flatten KS, Schneider PA, Dai NT, McDonald JS, Poirier GG, Kaufmann SH.
    J Biol Chem; 2012 Feb 03; 287(6):4198-210. PubMed ID: 22158865
    [Abstract] [Full Text] [Related]

  • 11. The ups and downs of Poly(ADP-ribose) Polymerase-1 inhibitors in cancer therapy-Current progress and future direction.
    Zhao Y, Zhang LX, Jiang T, Long J, Ma ZY, Lu AP, Cheng Y, Cao DS.
    Eur J Med Chem; 2020 Oct 01; 203():112570. PubMed ID: 32717529
    [Abstract] [Full Text] [Related]

  • 12. Avoid the trap: Targeting PARP1 beyond human malignancy.
    Kim C, Chen C, Yu Y.
    Cell Chem Biol; 2021 Apr 15; 28(4):456-462. PubMed ID: 33657415
    [Abstract] [Full Text] [Related]

  • 13. Systematic inhibitor selectivity between PARP1 and PARP2 enzymes: Molecular implications for ovarian cancer personalized therapy.
    Zuo X, Zhao H, Li D.
    J Mol Recognit; 2021 Jul 15; 34(7):e2891. PubMed ID: 33684965
    [Abstract] [Full Text] [Related]

  • 14. PARP1: A Promising Target for the Development of PARP1-based Candidates for Anticancer Intervention.
    Zhu X, Ma X, Hu Y.
    Curr Med Chem; 2016 Jul 15; 23(17):1756-74. PubMed ID: 25245372
    [Abstract] [Full Text] [Related]

  • 15. Discovery of isoquinolinone and naphthyridinone-based inhibitors of poly(ADP-ribose) polymerase-1 (PARP1) as anticancer agents: Structure activity relationship and preclinical characterization.
    Karche NP, Bhonde M, Sinha N, Jana G, Kukreja G, Kurhade SP, Jagdale AR, Tilekar AR, Hajare AK, Jadhav GR, Gupta NR, Limaye R, Khedkar N, Thube BR, Shaikh JS, Rao Irlapati N, Phukan S, Gole G, Bommakanti A, Khanwalkar H, Pawar Y, Kale R, Kumar R, Gupta R, Praveen Kumar VR, Wahid S, Francis A, Bhat T, Kamble N, Patil V, Nigade PB, Modi D, Pawar S, Naidu S, Volam H, Pagdala V, Mallurwar S, Goyal H, Bora P, Ahirrao P, Singh M, Kamalakannan P, Naik KR, Kumar P, Powar RG, Shankar RB, Bernstein PR, Gundu J, Nemmani K, Narasimham L, George KS, Sharma S, Bakhle D, Kamboj RK, Palle VP.
    Bioorg Med Chem; 2020 Dec 15; 28(24):115819. PubMed ID: 33120078
    [Abstract] [Full Text] [Related]

  • 16. Discovery of the PARP (poly ADP-ribose polymerase) inhibitor 2-(1-(4,4-difluorocyclohexyl)piperidin-4-yl)-1H-benzo[d]imidazole-4-carboxamide for the treatment of cancer.
    Tang L, Wu W, Zhang C, Shi Z, Chen D, Zhai X, Jiang Y.
    Bioorg Chem; 2021 Sep 15; 114():105026. PubMed ID: 34186467
    [Abstract] [Full Text] [Related]

  • 17. Identification of poly(ADP-ribose)polymerase 1 and 2 (PARP1/2) as targets of andrographolide using an integrated chemical biology approach.
    Li W, Pan B, Shi Y, Wang M, Han T, Wang Q, Duan G, Fu H.
    Chem Commun (Camb); 2021 Jun 24; 57(51):6308-6311. PubMed ID: 34075974
    [Abstract] [Full Text] [Related]

  • 18. Mortaparib, a novel dual inhibitor of mortalin and PARP1, is a potential drug candidate for ovarian and cervical cancers.
    Putri JF, Bhargava P, Dhanjal JK, Yaguchi T, Sundar D, Kaul SC, Wadhwa R.
    J Exp Clin Cancer Res; 2019 Dec 19; 38(1):499. PubMed ID: 31856867
    [Abstract] [Full Text] [Related]

  • 19. Poly (ADP-Ribose) Polymerases (PARPs) and PARP Inhibitor-Targeted Therapeutics.
    Li N, Wang Y, Deng W, Lin SH.
    Anticancer Agents Med Chem; 2019 Dec 19; 19(2):206-212. PubMed ID: 30417796
    [Abstract] [Full Text] [Related]

  • 20. Effect and mechanism of poly (ADP-ribose) polymerase-1 in aldosterone-induced apoptosis.
    Qiao W, Zhang W, Shao S, Gai Y, Zhang M.
    Mol Med Rep; 2015 Aug 19; 12(2):1631-8. PubMed ID: 25872931
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.